Investor FAQs

Investor FAQs

What does Fibrocell do?
Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma.
Where is the company located?
Fibrocell is located at 405 Eagleview Boulevard, Exton, PA 19341, USA. The main office telephone number is (484) 713-6000 and fax number is (484) 713-6001.
Where is the company incorporated?
Fibrocell is incorporated in the state of Delaware.
When does the fiscal year end for Fibrocell?
December 31
Where can I obtain corporate news releases?

The company’s news releases are archived on our Press Releases pages.

How can I view documents filed by Fibrocell with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q, proxy statements and other filings?
You can view the SEC filings for Fibrocell on our SEC Filings page or at www.sec.gov.
How can I find information on career opportunities with Fibrocell?
Visit our Careers page to learn more about career opportunities
Who should I contact with any other questions about Fibrocell?
Click here to submit your inquiries.